Publications by authors named "Ferdinand Luger"
Article Synopsis
- Enfortumab vedotin (EV) is a new treatment option for patients with advanced urothelial carcinoma who haven't responded to other therapies.
- A study involving 128 patients in Austria showed an objective response rate of 31%, with median progression-free survival of 4.8 months and overall survival of 10.75 months.
- The treatment was found to be feasible and effective, with an acceptable safety profile, although lower efficacy was noted compared to earlier trials, likely due to the patient population being in later therapy lines.
Article Synopsis
- Two randomized trials have established that triplet therapy (androgen deprivation therapy, ARPI, and docetaxel) provides better survival rates compared to doublet therapy (ADT and docetaxel) for patients with metastatic hormone-sensitive prostate cancer.
- A real-world analysis involving 97 mHSPC patients from various Austrian centers was conducted, tracking treatment responses and clinical parameters, while certain guideline-based treatments were underutilized in a significant percentage of the patients.
- Findings showed that patients who started ARPI after chemotherapy had better treatment responses, while 61.9% experienced adverse events, yet all patients had a notable decline in PSA levels, indicating treatment effectiveness.
Due to the increasing accessibility, molecular diagnostics are becoming more important in urology. There are validated predictive and prognostic biomarkers available for prostate cancer. This has clinical implications for screening diagnosis and personalized treatment options.
View Article and Find Full Text PDFObjective: To compare the efficacy of multiparametric magnetic resonance imaging (mpMRI)-directed and micro-ultrasonography (micro-US)-directed biopsy for detecting clinically significant (Grade Group >1) prostate cancer (csPCa).
Materials And Methods: A total of 203 patients were prospectively enrolled at three institutions across Germany and Austria in the period from January 2019 to December 2019. During each biopsy, the urologist was blinded to the mpMRI report until after the micro-US targets had been assessed.
Introduction: High-resolution micro-ultrasound has the capability of imaging prostate cancer based on detecting alterations in ductal anatomy, analogous to multiparametric magnetic resonance imaging (mpMRI). This technology has the potential advantages of relatively low cost, simplicity, and accessibility compared to mpMRI. This multicenter, prospective registry aims to compare the sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of mpMRI with high-resolution micro-ultrasound imaging for the detection of clinically significant prostate cancer.
View Article and Find Full Text PDFBackground: Knowledge about the staging significance of the prostate cancer antigen 3 (PCA3) score to better identify pathologic features after radical prostatectomy (RP) is limited and controversial.
Objective: Our aim was to study the clinical staging significance of PCA3 to identify pathologic favorable and/or unfavorable features in the RP specimen.
Design, Setting, And Participants: Complete retrospective clinical and pathologic data of consecutive men who had undergone RP from three tertiary referral centers including preoperative PCA3 scores (n=305) and computer-assisted planimetrically measured tumor volume data (n=160) were available.